The Relative Strength (RS) Rating for Edwards Lifesciences climbed into a new percentile Wednesday, as it got a lift from 69 to 74.
When To Sell Stocks To Lock In Profits And Minimize Losses
This exclusive rating from Investor's Business Daily identifies share price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the top-performing stocks often have an RS Rating of over 80 as they launch their biggest runs. See if Edwards Lifesciences can continue to show renewed price strength and clear that threshold.
Edwards Lifesciences is working on a flat base with an 83.00 entry. See if it can break out in heavy volume.
While earnings-per-share growth fell in the company's most recently reported quarter from 16% to 8%, revenue rose 12%, up from 6% in the previous report.
The company earns the No. 11 rank among its peers in the Medical-Products industry group. Insulet, Boston Scientific and LivaNova are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
